Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus-induced demyelinating disease by modifying the Nrf2-Keap1 pathway

Kunitoshi Kobayashi, Hiroki Tomiki, Yuji Inaba, Motoki Ichikawa, Byung S. Kim, Chang Sung Koh*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Dimethyl fumarate (DMF) is a modifier of the nuclear factor (erythroid-derived 2)-2 (Nrf2)-kelchlike ECH-associated protein 1 (Keap1) pathway. DMF treatment in the effector phase significantly suppressed the development of Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD) both clinically and histologically. DMF treatment leads to an enhanced Nrf2 antioxidant response in TMEV-IDD mice. DMF treatment in the effector phase significantly suppressed the level of IL-17A mRNA. DMF is known to inhibit differentiation of T helper 17 (Th17) cells via suppressing NF-κB. Taken together, our data suggest that DMF treatment in the effector phase may suppress TMEV-IDD not only via enhancing the antioxidant response but also via suppressing IL-17A.

Original languageEnglish (US)
Pages (from-to)333-344
Number of pages12
JournalInternational Immunology
Volume27
Issue number7
DOIs
StatePublished - Jul 1 2015

Keywords

  • Dimethyl fumarate (DMF)
  • Multiple sclerosis (MS)
  • Nrf2-Keap1 pathway
  • TMEV-induced demyelinating disease (TMEV-IDD)
  • Theiler's murine encephalomyelitis virus (TMEV)

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Dimethyl fumarate suppresses Theiler's murine encephalomyelitis virus-induced demyelinating disease by modifying the Nrf2-Keap1 pathway'. Together they form a unique fingerprint.

Cite this